Compliance requirements for the pharmaceutical industry and impact on marketing practices
This presentation is the property of its rightful owner.
Sponsored Links
1 / 33

Compliance Requirements for the Pharmaceutical Industry and Impact on Marketing Practices PowerPoint PPT Presentation


  • 80 Views
  • Uploaded on
  • Presentation posted in: General

Compliance Requirements for the Pharmaceutical Industry and Impact on Marketing Practices . Timothy M. Cunniff, Pharm.D. Vice President, Global Regulatory Affairs Lundbeck Inc. May 2009. Disclosure Statement. Employee of Lundbeck Inc. (formerly Ovation Pharmaceuticals). Objectives.

Download Presentation

Compliance Requirements for the Pharmaceutical Industry and Impact on Marketing Practices

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Compliance requirements for the pharmaceutical industry and impact on marketing practices

Compliance Requirements for the Pharmaceutical Industry and Impact on Marketing Practices

Timothy M. Cunniff, Pharm.D.

Vice President, Global Regulatory Affairs

Lundbeck Inc.

May 2009


Disclosure statement

Disclosure Statement

  • Employee of Lundbeck Inc. (formerly Ovation Pharmaceuticals)


Objectives

Objectives

  • Describe the various legal, regulatory and industry compliance standards

  • Discuss requirements applicable to industry interaction with healthcare professionals

  • Summarize recent revisions to the PhRMA code and impact on pharmaceutical marketing practices


Legal basis for industry compliance programs

Legal Basis for Industry Compliance Programs

  • Federal and State Laws

    • Food, Drug and Cosmetic Act (21 U.S.C. 301 et. seq.)

    • Anti-Kickback Statute (42 U.S.C. & 1320a-7b[b])

    • Civil False Claims Act (31 U.S.C. 3729)

    • Fraud and Abuse Investigations and Prosecutions

    • General Criminal Fraud Statutes

    • Whistle Blower Act (31 U.S.C. 3730)

  • HHS Guidance

    • OIG

    • FDA

  • Industry and Medical Organization Recommendations

    • PhRMA

    • AMA


Recent industry settlements for compliance violations

Recent Industry Settlements for Compliance Violations

  • Bayer: $14MM

  • TAP:$875MM

  • Abbott: $600MM

  • Schering–Plough:$435MM

  • Pfizer: $430MM

  • Serono: $704MM

  • Eli Lilly:$1.42BB


Significant compliance standards for industry

Significant Compliance Standards for Industry

  • July 2002: PhRMA Code on Interaction with Healthcare Professionals

  • April 2003: OIG Compliance Program guidance

  • July 2005: California Law

    • Required industry to adopt policies that ensure compliance with OIG and PhRMA Code guidelines

  • January 2009: Revised PhRMA Code


Oig compliance program guidance

OIG Compliance Program Guidance

  • Stresses the importance of the development and implementation of a functional compliance program

  • Cautions the pharmaceutical industry in three high risk areas

  • Identifies exemptions or “safe harbors” for federal and state healthcare programs

  • Utilized to decrease the risk of fraud and abuse in federally funded health care programs


Oig compliance program guidance three potential areas of risk

OIG Compliance Program GuidanceThree Potential Areas of Risk

  • Accurate price and sales reporting to government agencies

  • Kickbacks and other illegal remunerations

  • Drug samples


Oig potential area of risk accurate price and sales reporting

OIG: Potential Area of RiskAccurate Price and Sales Reporting

  • Accounting for price reductions, cash discounts, rebates, coupons, etc. for purchasers

  • Data submitted used to calculate AMWP and Best Price

  • Impacts reimbursement rates under Medicare and Medicaid

  • Violations covered by False Claims Act

    • Prohibits knowingly presenting to the federal government a false or fraudulent claim, or false record, to get a payment or false claim approved

    • Civil monetary penalties


Oig potential area of risk kickbacks and other illegal remuneration

OIG: Potential Area of RiskKickbacks and Other Illegal Remuneration

Anti-kickback Statute

  • Criminal prohibition against payments made purposefully to induce or reward the referral or generation of federal health care business

    Identifying potential risk behavior

  • Determine remunerative relationships

  • Is any one purpose of remuneration unlawful?


Oig kickbacks other illegal remuneration relationships of concern

OIG:Kickbacks & Other Illegal RemunerationRelationships of Concern

  • Manufacturer-Purchasers

    • Including those using formularies and their agents

  • Manufacturer-Physician

    • Including persons and entities in a position to make or influence referrals

  • Manufacturer-Sales Agent


Oig relationships of concern manufacturer purchaser relationship

OIG: Relationships of ConcernManufacturer-Purchaser Relationship

  • Discounts

  • Formulary Support Activities

  • Average Wholesale Price

    • Pharmaceutical companies have ability to control the AWP and indirectly influence customer’s profit

    • Wrongfully manipulating AWP violates anti-kickback statue


Oig relationships of concern manufacturer physician relationship

OIG: Relationships of ConcernManufacturer-Physician Relationship

  • Consulting

  • Educational Grants

  • Research Funding

  • Business courtesies and other gratuities


Oig manufacturer physician relationship consulting

OIG: Manufacturer-Physician RelationshipConsulting

  • Signed agreement for consulting services

    • Fair market value

    • Services pre-specified contractually

  • Legitimate need

  • Service is actually provided


Oig manufacturer physician relationship educational grants

OIG: Manufacturer-Physician RelationshipEducational Grants

  • Unrestricted grant for a defined program

  • Independent from sales & marketing

  • Defined criteria

  • Awarded to conference sponsor

  • Industry cannot select speakers or control the agenda


Oig manufacturer physician relationship research funding

OIG: Manufacturer-Physician RelationshipResearch Funding

  • Independent from sales & marketing

  • Fair market value

  • Legitimate and necessary

  • No “seeding” trials allowed

  • Clinical Officer conducts review of research


Oig manufacturer physician relationship business courtesies other gratuities

OIG: Manufacturer-Physician RelationshipBusiness Courtesies/Other Gratuities

  • Determine and publicly document annual allotted amount

  • Meals

    • Modest

    • Industry representative present

    • Venue must be conducive for education

    • Entertainment prohibited

    • No Guests

  • Gifts/Reminder Items

    • Educational purposes only and should benefit patients


Oig kickbacks other illegal remuneration manufacturer sales agent relationship

OIG: Kickbacks & Other Illegal RemunerationManufacturer-Sales Agent Relationship

  • Compensation and Bonuses Practices

  • Expense accounts

  • Regular PhRMA Code training

  • Audit and review sales force activities


Oig potential area of risk drug samples

OIG: Potential Area of RiskDrug Samples

  • Selling drug samples or submitting claims for drug samples is unlawful

    • Prescription Drug Marketing Act of 1987 (PDMA)

    • False Claims Act

    • Anti-kickback statue

  • Label drug samples appropriately

  • Reconcile and account for drug sample distribution


Phrma code

PhRMA CODE

  • Originally issued in 2002 and revised in 2008 (effective January 1, 2009)

    • Addresses industry’s relationships with healthcare professionals with respect to marketed products and pre-launch activities

      • Ethical standards of conduct

      • Compliance with legal requirements

    • Goal is to benefit patients and enhance the practice of medicine

    • “Voluntary” for PhRMA member companies (not law)


Phrma code informational presentations

2002 Version

Occasional meals may be offered

Modest

Conducive venue

Provide educational value

Company representative present

No guests

No entertainment

2009 Revision

Outside meals with sales representatives not allowed

PhRMA CodeInformational Presentations


Phrma code third party educational meetings

2002 Version

Financial support for CME allowed

Funding via program sponsor

Cannot control content, faculty, materials or venue

Cannot reimburse travel for attendees

Can provide meals and receptions

2009 Revision

Follow ACCME standards or other entity that may accredit CME

Sales & Marketing cannot make grants

Industry cannot provide meals or receptions at CME events

PhRMA CodeThird Party Educational Meetings


Phrma code consultants

2002 Version

Reasonable compensation for services and reimbursement for travel expenses

Written contract

Legitimate need

Criteria for selection

Number of consultants

Venue is appropriate

Social events subordinate

2009 Revision

No changes

PhRMA CodeConsultants


Phrma code speaker training meetings

2002 Version

Reasonable compensation and reimbursement for travel allowed

Must receive extensive training on product AND on compliance with FDA regulatory requirements

2009 Revision

Firms to set a maximum amount per speaker

Number of speakers and number of engagements per speaker should be limited

Training should not be at “resort” settings

Must draw distinction between speaker’s programs and CME

Healthcare professionals should disclose relationship away form podium and for at least 2 years beyond termination of relationship

PhRMA CodeSpeaker Training Meetings


Phrma code educational practice related items

2002 Version

Items that primarily benefit patients allowed

Not substantial value ($100 or less)

Occasional basis only

Practice-related items allowed

Minimal value

Must not provide a personal benefit

2009 Revision

Items must primarily benefit the education of patients or healthcare providers

Not substantial value

Occasional basis only

Practice-related items not allowed

What, No Pens!

PhRMA CodeEducational & Practice Related Items


Phrma code potential future revisions

PhRMA CodePotential Future Revisions

  • Revision of Direct-to-Consumer advertising principles

    • DTC principles first described in 2005

    • Proposed revisions may cite standards developed by outside groups (i.e., AMA)

    • Congressional pressure by Reps. John Dingell (D-Mich) and Bart Stupak (D-Mich) is driving reform


Phrma code impact of 2009 revisions

PhRMA CodeImpact of 2009 Revisions

  • Corporate compliance is paramount

    • SOPs- Hundreds!

    • Multiple approvals/Committee reviews

    • Training

    • Auditing

    • Disciplinary action

      • Individuals

      • Firms (i.e., ABPI suspension of Roche)

  • Many firms likely to scale back on marketing

    • Global economic crisis

    • Massive number of patent expirations

    • PhRMA code provides some assurance that firms aren’t unilaterally reducing marketing spend


State regulation of industry marketing practice one example

State Regulation of Industry Marketing Practice- One Example

  • Massachusetts

    • Code of Conduct effective July 1, 2009

      • Each firm must adopt a marketing Code of Conduct

      • Submit description of training program for appropriate employees to document knowledge of:

        • Code of Conduct

        • General science

        • Product-specific information

      • Bans practice-related items (i.e., pens)

      • Certify compliance with state law

      • Adopt and submit polices for investigating non-compliance


Lundbeck s corporate compliance program

Lundbeck’s Corporate Compliance Program

  • Written code of conduct and ethical principles

    • Certify compliance with PhRMA Code on an annual basis (CCO and CEO)

  • Focus on specific “risk” areas

  • Effective training and education

  • Established lines of communication and processes to respond to issues


Lundbeck s corporate compliance program cont

Lundbeck’s Corporate Compliance Program (cont.)

  • Oversight and monitoring

    • Primary: Compliance Officer

    • Secondary: Compliance Committee

    • Tertiary: President and CEO

    • Final: Board of Directors

  • Enforcement of standards through progressive discipline

  • Internal audit functions


Lundbeck compliance policies

Lundbeck Compliance Policies

  • Lundbeck has well over 100 substantive polices and procedures including:

    • Meals, gifts and entertainment

    • Consulting agreements for healthcare providers

    • Medical education grants

    • Commercial program support

    • Advertising and Promotion

    • Dissemination of published literature

    • Prescription drug marketing and sampling

    • Medical Science Liaison policy

    • Medical Information response policy


Lundbeck compliance committees

Lundbeck Compliance Committees

  • Promotional Advertising Review Committee

    • Legal/Compliance, Regulatory, Medical, Marketing

  • Medical Grant Review Committee

    • Legal/Compliance, Regulatory, Medical, Finance, Marketing

  • Corporate Compliance Committee

    • Legal. Regulatory, Clinical, Medical, Human Resources, Finance, Marketing


Questions

Questions?


  • Login